• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Business Research >Effects of price cap regulation on the pharmaceutical supply chain
【24h】

Effects of price cap regulation on the pharmaceutical supply chain

机译：价格上限监管对药品供应链的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This paper considers a pharmaceutical supply chain composed of one pharmaceutical manufacturer and one pharmacy. We investigate how price cap regulation affects pharmaceutical firms' pricing decisions. We also evaluate the economic and social performance of the pharmaceutical supply chain and assess the risks associated with price cap regulation. The derived equilibriums under different price cap regulations, including retailer price cap regulation, manufacturer price cap regulation and linkage price cap regulation, are compared to that without regulation. Our results show that one-sided price cap regulation will damage the economic performance of the regulated firm, whereas the unregulated firm may gain a financial advantage. The regulation may increase the risk of a supply shortage if pharmaceutical firms cannot cope with the financial loss. In contrast, linkage price cap regulation can be an effective policy for improving both the economic and social performance of the pharmaceutical supply chain.
机译：本文考虑由一个药品制造商和一个药房组成的药品供应链。我们调查价格上限监管如何影响制药公司的定价决策。我们还评估了药品供应链的经济和社会绩效，并评估了与价格上限监管相关的风险。将不同价格上限法规（包括零售商价格上限法规，制造商价格上限法规和关联价格上限法规）下得出的均衡与没有监管的情况进行比较。我们的结果表明，单方面的价格上限监管将损害受监管公司的经济绩效，而未受监管的公司可能会获得财务优势。如果制药公司无法应对财务损失，该法规可能会增加供应短缺的风险。相反，联动价格上限监管可能是改善药品供应链经济和社会绩效的有效政策。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号